An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pamiparib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors BeiGene

01 Feb 2023 Results assessing the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2-) breast cancer published in the Breast Cancer Research and Treatment
08 Jun 2021 Status changed from active, no longer recruiting to completed, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com